PlainRecalls
FDA Drug Moderate Class II Ongoing

Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel.

Reported: February 12, 2025 Initiated: January 10, 2025 #D-0218-2025

Product Description

Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel.

Reason for Recall

Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit

Details

Units Affected
34,636 cartons
Distribution
Product was distributed nationwide.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled? ▼
Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel.. Recalled by Teva Pharmaceuticals USA, Inc. Units affected: 34,636 cartons.
Why was this product recalled? ▼
Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
Which agency issued this recall? ▼
This recall was issued by the FDA Drug on February 12, 2025. Severity: Moderate. Recall number: D-0218-2025.

Related Recalls

FDA Drug Moderate

Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: U…

Unichem Pharmaceuticals USA Inc. · 2026-02-11
FDA Drug Critical

Green Lumber Natural Fuel For Men capsule, packaged in 2, 4, 10, and 30-count blister packs. GreenLumber.com, 2618 San…

Green Lumber Holdings, LLC · 2026-02-11
FDA Drug Moderate

Trazodone Hydrochloride, USP, 50 mg, 100-Count Bottle, Rx only, Manufactured by: Granules India Limited, Hyderabad, 500…

Granules Pharmaceuticals Inc. · 2026-02-11
FDA Drug Critical

Diclofenac Sodium, Topical Gel, 3%, 100 g, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1…

SUN PHARMACEUTICAL INDUSTRIES INC · 2026-02-11
FDA Drug Critical

Rheumacare capsules, 30 count bottle, Mfg in India by: Virgo UAP Pharma Pvt. Ltd., Ahmedabad, India UPC 8 904218 700313

HANDELNINE GLOBAL LLC · 2026-02-11

Explore Related Data

Vehicle Safety → Drug Information →